Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
2333 CR Leiden
Pharming Group NV is a leading, independent biotechnology company based in Leiden, The Netherlands. Pharming has a long history, and a broad product pipeline with therapies for several indications and in different stages of development. Today’s lead therapy is RUCONEST for treatment of acute attacks of HAE. Pharming’s technologies include innovative platforms for the production of protein therapeutics, technology, and processes for the purification and formulation of these therapies.
RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in the USA, Israel, all 28 EU countries plus Norway, Iceland and Liechtenstein. RUCONEST is distributed directly in Germany, Austria, and the Netherlands by Pharming and in the rest of the EU by Swedish Orphan Biovitrum AB (Sobi). In the USA, Pharming has a partnership with Salix Pharmaceuticals to market this therapy.
RUCONEST is a non-blood derived human C1 inhibitor that is made in rabbits. Clinical trials have shown that RUCONEST is a safe and effective treatment for acute HAE attacks.